Male doctor looking at the camera

Bring clarity to prostate cancer diagnosis

Improving prostate cancer detection for more patients

Precise, personalized care starts here


Early and accurate diagnosis leads to clear options for treatment. Unfortunately, standard TRUS prostate biopsies are often imprecise, with the ability to detect only 30-41% of cancers.1 Philips offers a comprehensive prostate cancer diagnosis solution by utilizing MRI/Ultrasound fusion currently in use at 22 of the 25 of the top cancer hospitals in the US.2 This unified, orchestrated approach to prostate cancer diagnosis and care has significant benefits for clinical teams and for patients.


This more targeted approach can benefit patients by potentially reducing instances of biopsy-related hospitalization, decreasing the likelihood of sepsis, and most importantly, avoiding the need for repeat biopsies.3 Whichever method is chosen, ensuring that patients have the highest quality care possible can be complicated given the many specialties involved in the prostate cancer journey, such as urology, radiology, pathology, genomics and oncology. Inefficient and disconnected workflows further complicate the picture.

Did you know?

One out of six person icon

1/6 men in US/Europe will be diagnosed with prostate cancer during their lifetime4.

Thirty percent icon

TRUS is still the most common form of biopsy for prostate cancer detection, but MRI-targeted biopsies have been shown to improve diagnosis of high-risk cancers by 30%5.

Undertreatment and overtreatmen icon

Due to inaccurate risk profiling, up to 40% of aggressive prostate cancers are undertreated6 and up to 50% of insignificant prostate cancers are overtreated7.

Troubling inequities in diagnosis and outcomes

Seventy three percent higher icon

Black men have an incidence of prostate cancer that is almost 73% higher than white men8.

Twice likely icon

Black men are almost twice as likely to be diagnosed with prostate cancer as white men, and more than twice as likely to die from the disease9.

Clinician in consultation checking MR scans on a computer screen

High-quality prostate cancer care is personalized for each patient

Philips provides the tools needed for patient-centered MR imaging, advanced visualization and reporting, MR/fusion-guided biopsies, digital pathology and genomic insights. This integrated approach unites urology, radiology, pathology, genomics and oncology with an end-to-end flow of data that streamlines workflows, enhances collaboration for more confidence, delivers meaningful insights and helps support quality of life for patients with prostate cancer. Our clinical solutions can further enhance the patient experience by reducing unnecessary biopsies and post-procedure complications.

Key capabilities for clarity in prostate cancer diagnosis



    UroNav fuses pre-biopsy MR images of the prostate with ultrasound-guided biopsy images in real time, for excellent delineation of the prostate and suspicious lesions, as well as clear visualization of the biopsy needle path. Combining electromagnetic tracking and navigation with an onboard computer and a real-time imaging interface, UroNav brings precision targeting to your clinical practice in one easy-to-use, mobile workstation.


    DynaCAD Prostate  

    Philips DynaCAD Prostate is an advanced visualization system that empowers you with a comprehensive set of tools for real-time analysis, review, and reporting of multi-parametric MRI studies. Create time and workflow efficiency by transferring images directly from the MRI to DynaCAD. Utilize its robust, automatic post-processing tools and display results in customized hanging protocols for analysis and reporting. At case completion, you can automatically transfer key images, statistical data, and prostate PI-RADS® reports to PACS for archiving. By setting everything up for you to work, DynaCAD helps you enhance your confidence and productivity – so patients get the prompt, precise care they need.


    DynaCAD Urology  

    DynaCAD Urology is a purpose build solution that empowers urologists with a dedicated set of tools for utilizing multi-parametric MR data in fusion biopsy workflows. It also provides a solution for managing patients’ biopsy data in urology.

Look to the leaders banner

Look to the leaders

Philips solutions for prostate cancer diagnosis are in use at 22 of the top 25 ranked US hospitals for cancer2

Results you can measure

Our clinical solutions can enhance detection and improve the patient experience by reducing unnecessary biopsies and potentially reducing post-procedure complications. Digital pathology saves time and resources through streamlined collaborative features and case management tools.


improvement in high-risk prostate cancer diagnosis using fusion biopsy vs standard biopsy5


reduction in pathological upgrading to clinically significant prostate cancer with targeted and systematic biopsies vs systematic biopsies alone5


increase in prostate cancers identified with combined targeted and systematic biopsy compared ​to systematic biopsy alone10


hours/day saved through increased lab efficiency by using digital pathology workflows11


faster MRI scans using Compressed SENSE with virtually equal image quality12

Would you like to know more about how we can help your prostate cancer program?​

Philips can assess where you are today so you can build an approach to improve prostate cancer diagnosis by integrating urology, radiology, pathology, genomics and oncology. Discover how we can help you implement, manage and grow your prostate care program.

We are always interested in engaging with you.

Let us know how we can help.

Select your area of interest
Contact details

Results from case studies are not predictive of results in other cases. Results in other cases may vary.

1 Choi YH, et al. Comparison of cancer detection rates between TRUS-guided biopsy and MRI-targeted biopsy according to PSA level in biopsy-naive patients: a propensity score matching analysis. Clin Genitourin Cancer. 2019 Feb;17(1):e19-e25. doi: 10.1016/j.clgc.2018.09.007. Epub 2018 Sep 13. PMID: 30415878.
2 U.S. News and World Report: 2017 Best Hospitals Ranking (Cancer)
3 Yarlagadda VK, et al. MRI/US fusion-guided prostate biopsy allows for equivalent cancer detection with significantly fewer needle cores in biopsy-naive men. Diagn Interv Radiol. 2018 May-Jun;24(3):115-120. doi: 10.5152/dir.2018.17422. PMID: 29770762; PMCID: PMC5951198.
4 WHO Cancer fact sheet No 297., American Cancer Society & SEER.
5 Siddiqui MM, et al. Comparison of MR/ultrasound fusion–guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA. 2015;313(4):390-397.
6 Sonn GA, et al. Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion device. J Urol. 2013 Jan;189(1):86-91. doi: 10.1016/j.juro.2012.08.095. Epub 2012 Nov 14. PMID: 23158413; PMCID: PMC3561472.
7 Loeb S, et al. Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014 Jun;65(6):1046-55. doi: 10.1016/j.eururo.2013.12.062.
8 American Cancer Society. Cancer Facts & Figures 2022. Atlanta: American Cancer Society; 2022
9 ZERO – The End of Prostate Cancer. New data highlights troubling trends for prostate cancer diagnoses. Alexandria, VA: ZERO; 2022.
10 PMID: 31298628. 12. Ahdoot M, et al. MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis. NEMJ. 2020382:917–928. doi: 10.1056/NEJMoa1910038
11 Baidoshvili A, et al. Evaluating the benefits of digital pathology implementation: time savings in laboratory logistics. Histopathology. 2018 Nov;73(5):784-794. doi: 10.1111/his.13691. Epub 2018 Aug 13. PMID: 29924891.
12 Compared to Philips scans without Compressed SENSE

You are about to visit a Philips global content page


You are about to visit a Philips global content page


Our site can best be viewed with the latest version of Microsoft Edge, Google Chrome or Firefox.